RUXIENCE Trademark

Trademark Overview

On Monday, July 2, 2018, a trademark application was filed for RUXIENCE with the United States Patent and Trademark Office. The USPTO has given the RUXIENCE trademark a serial number of 88023071. The federal status of this trademark filing is REGISTERED as of Tuesday, October 13, 2020. This trademark is owned by Pfizer Inc.. The RUXIENCE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of cancer
ruxience

General Information

Serial Number88023071
Word MarkRUXIENCE
Filing DateMonday, July 2, 2018
Status700 - REGISTERED
Status DateTuesday, October 13, 2020
Registration Number6175690
Registration DateTuesday, October 13, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 11, 2018

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, July 7, 2018
Primary Code005
First Use Anywhere DateFriday, January 31, 2020
First Use In Commerce DateFriday, January 31, 2020

Trademark Owner History

Party NamePfizer Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNew York, NY 100012192
Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Tuesday, March 28, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, March 28, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 28, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, March 28, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, March 28, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, October 13, 2020REGISTERED-PRINCIPAL REGISTER
Wednesday, September 9, 2020NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, September 8, 2020ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, August 26, 2020STATEMENT OF USE PROCESSING COMPLETE
Wednesday, August 12, 2020USE AMENDMENT FILED
Wednesday, August 26, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 12, 2020TEAS STATEMENT OF USE RECEIVED
Tuesday, July 28, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 24, 2020SOU EXTENSION 3 GRANTED
Friday, July 24, 2020SOU EXTENSION 3 FILED
Friday, July 24, 2020TEAS EXTENSION RECEIVED
Tuesday, January 14, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 10, 2020SOU EXTENSION 2 GRANTED
Friday, January 10, 2020SOU EXTENSION 2 FILED
Friday, January 10, 2020TEAS EXTENSION RECEIVED
Thursday, August 1, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 30, 2019SOU EXTENSION 1 GRANTED
Tuesday, July 30, 2019SOU EXTENSION 1 FILED
Tuesday, July 30, 2019TEAS EXTENSION RECEIVED
Tuesday, February 5, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 11, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 11, 2018PUBLISHED FOR OPPOSITION
Wednesday, November 21, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, October 26, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, October 23, 2018ASSIGNED TO EXAMINER
Saturday, July 7, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 5, 2018NEW APPLICATION ENTERED

Related Keywords

ruxience pharmaceutical treatment preparations cancer disorders autoimmune inflammatory diseases